97279 ⎘
Immunoglobulins specific features characterized by immunoglobulin fragments; Constant or Fc region; Isotype Hinge
ANTIGEN-BINDING MOLECULE COMPRISING ALTERED ANTIBODY VARIABLE REGION
#602ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS
#603MODIFIED FC FRAGMENT, ANTIBODY COMPRISING SAME, AND APPLICATION THEREOF
#604Anti-CD28 compositions
#605Chimeric engulfment receptor molecules
#606CONTROLLING PROXIMITY OF IMMUNE CELL RECEPTORS
#607ENGINEERED IMMUNE CELLS WITH MICRO-CLUSTERS
#608ENGINEERED IMMUNE CELLS WITH MULTIPLEX AND LOCALIZED ACTIVITY
#609Engineered immune cells with receptor cross-talk
#610ENGINEERING IMMUNE CELLS BASED ON ANTIGEN LEVELS
#611REMOVAL OF TARGET CELLS BY CIRCULATING VIRUS-SPECIFIC CYTOTOXIC T-CELLS USING MHC CLASS I COMPRISING COMPLEXES
#612MULTI-SPECIFIC PROTEIN MOLECULES AND USES THEREOF
#613Antibodies Directed Against Programmed Death-1 (PD-1)
#614ANTIGEN BINDING CONSTRUCTS TO TARGET MOLECULES
#615CHIMERIC ANTIGEN RECEPTORS WITH MODIFIED LINKER DOMAINS AND USES THEREOF
#616Anti-BCMA chimeric antigen receptors
#617Engineered immune cells with receptor signal strength modulated by a hinge
#618Engineered immune cells with dominant signals
#619Modified B cells and methods of use thereof
#620Antibodies with improved stability to intestinal digestion, polynucleotides thereof and methods of use thereof to treat disease
#621CHIMERIC ANTIGEN RECEPTOR MEMORY-LIKE (CARML) NK CELLS AND METHODS OF MAKING AND USING SAME
#622GENE MODIFIED IMMUNE EFFECTOR CELLS AND ENGINEERED CELLS FOR EXPANSION OF IMMUNE EFFECTOR CELLS
#623ANTIGEN BINDING FORMATS FOR RECEPTOR COMPLEXES
#624Multispecific antibodies against CD40 and CD137
#625MODIFIED ANTIBODIES
#626COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CTLA-4
#627Drug regulated transgene expression
#628ANTIBODY CONSTANT REGION VARIANT
#629Anti-human kallikrein-2 (hK2) chimeric antigen receptor (CAR) and methods of use thereof
#630Antibodies and Antigen Binding Fragments Against CD155 Methods of Use Thereof
#631Caninized human antibodies to human IL-4R alpha
#632ENGINEERED OPSONIN FOR PATHOGEN DETECTION AND TREATMENT
#633Compositions and methods related to engineered Fc constructs
#634Engineered immune cells targeting BCMA and their uses thereof
#635CR3022 chimeric antigen receptors and methods of use
#636CD3 antigen binding fragment and application thereof
#637Antibody molecules comprising a single-domain antigen-binding site and Fab fragments
#638ACTIVATABLE THERAPEUTIC MULTISPECIFIC POLYPEPTIDES WITH EXTENDED HALF-LIFE
#639Multispecific antibodies against CD40 and CD137
#640CHIMERIC ANTIGEN RECEPTOR-MODIFIED NK-92 CELLS TARGETING EGFR SUPER-FAMILY RECEPTORS
#641Anti-ETEC adhesin protein antibodies and methods of use
#642Articles and methods directed to personalized therapy of cancer
#643Dual cytokine fusion proteins comprising IL-10
#644METHOD FOR PRODUCING POLYPEPTIDE HETERO-OLIGOMER
#645Constructs for chimeric antigen receptors
#646Production of heteromultimeric proteins using mammalian cells
#647Method of increasing tumor killing activity of macrophages or monocytes comprising chimeric antigen receptor
#648NOVEL CONSTRUCTS FOR CHIMERIC ANTIGEN RECEPTORS
#649Chimeric antigen receptor
#650Chimeric antigen receptors against multiple HLA-G isoforms
#651HLA binding vaccine moieties and uses thereof
#652CHIMERIC ANTIGEN RECEPTOR T LYMPHOCYTE FOR TREATING TUMORS, PREPARATION METHOD THEREFOR, AND USE THEREOF
#653Anti-PSGL-1 antibodies and uses thereof
#654Anti-Met fab-Fc for the treatment of a tumor and/or metastasis
#655METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#656CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders
#657METHODS FOR TREATMENT USING CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN
#658Bispecific antibody which binds to CD40 and EpCAM
#659ANTIBODY COMPOSITION
#660ANTIGEN BINDING CONSTRUCTS TO CD4
#661HOMODIMERIC BISPECIFIC ANTIBODY, PREPARATION METHOD THEREFOR AND USE THEREOF
#662HUMANIZED RODENTS THAT EXPRESS HEAVY CHAIN CONTAINING VL DOMAINS
#663Rat model of IgA nephropathy induced with a multimeric recombinant IgA fragment
#664PROTEIN BINDING NKG2D, CD16 AND A FIBROBLAST ACTIVATION PROTEIN
#665PD-1 variant immunomodulatory proteins and uses thereof
#666Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
#667NON-HUMAN ANIMALS THAT SELECT FOR LIGHT CHAIN VARIABLE REGIONS THAT BIND ANTIGEN
#668IL10 agonists and methods of use thereof
#669CONTORSBODY - A SINGLE CHAIN TARGET BINDER
#670MODIFIED ANTIBODIES CONTAINING MODIFIED IGG2 DOMAINS WHICH ELICIT AGONIST OR ANTAGONISTIC PROPERTIES AND USE THEREOF
#671Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors
#672VEGF traps and mini-traps and methods for treating ocular disorders and cancer
#673Fc-epsilon car
#674Rapamycin resistant cells
#675FUSION POLYPEPTIDE COMPRISING POLYPEPTIDE REGION THAT CAN BE O-GLYCOSYLATED
#676ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY POLYPEPTIDES
#677ARTICLES AND METHODS DIRECTED TO PERSONALIZED THERAPY OF CANCER
#678Compositions and methods of treating cancer with chimeric antigen receptors
#679Bispecific 2+1 contorsbodies
#680BISPECIFIC ANTIBODIES AGAINST HER2
#681CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN AND ENCODING POLYNUCLEOTIDES
#682Affinity matured CD22-specific monoclonal antibody and uses thereof
#683HEAVY CHAIN ONLY ANTIBODIES TO ANG-2
#684ApoC-II mimetic peptides
#685COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
#686Multispecific antibodies against CD40 and CD137
#687MULTI-SPECIFIC BINDING PROTEINS THAT BIND BCMA, NKG2D AND CD16, AND METHODS OF USE
#688IMMUNOMODULATORY ANTIBODIES
#689ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#690ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#691Enhanced antigen presenting ability of RNA car T cells by co-introduction of costimulatory molecules
#692TAG72 targeted chimeric antigen receptor modified T cells for treatment of TAG72-positive tumors
#693Methods and compositions for treating autoimmune and inflammatory conditions
#694ENGINEERED PHAGOCYTIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF
#695PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#696COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC-ANTIGEN BINDING DOMAIN CONSTRUCTS
#697CD70 binding molecules and methods of use thereof
#698ANTI-C-MET ANTIBODY AND USES THEREOF
#699Methods of use of CD24 for the prevention and treatment of leukemia relapse
#700CHIMERIC ANTIGEN RECEPTORS TARGETING CD37 AND CD19
#701Notch receptors with hinge domain
#702PROTEINS BINDING NKG2D, CD16, AND EGFR, CCR4, OR PD-L1
#703CD79A chimeric antigen receptors
#704Chimeric antigen receptor-modified NK-92 cells
#705BISPECIFIC ANTIBODIES
#706Modified immunoglobulin hinge regions to reduce hemagglutination
#707Compositions and Methods for Retrieving Tumor-related Antibodies and Antigens
#708Universal T cells and the method of use thereof
#709MODIFIED GAMMA DELTA T CELLS AND USES THEREOF
#710FC-REGION VARIANTS WITH MODIFIED FCRN- AND PROTEIN A-BINDING PROPERTIES
#711EphA3 directed CAR-T cells for treatment of tumors
#712Antibodies Comprising Chimeric Constant Domains
#713COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
#714ALLOGENEIC TUMOR CELL VACCINE
#715Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
#716DIMERIC PROTEIN WITH TRIPLE MUTATIONS
#717Anti-PD1 antibodies and their use as therapeutics and diagnostics
#718USE OF INHIBITORY CHIMERIC RECEPTORS TO PREVENT T CELL-INDUCED BLOOD BRAIN BARRIER DAMAGE
#719Compositions and methods related to engineered Fc constructs
#720Anti-BCMA chimeric antigen receptors
#721CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#722Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
#723Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
#724FC-EPSILON CAR (Very imp commercially - in clinical trial)
#725Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
#726Anti-PVRIG antibodies and methods of use
#727ANTIBODY HALF-MOLECULE, AND METHOD FOR INHIBITING HOMODIMER FORMATION OF ANTIBODY HALF-MOLECULE
#728Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies
#729Lysine conjugated immunoglobulins
#730LEUCINE ZIPPER-BASED COMPOSITIONS AND METHODS OF USE
#731CS1 targeted chimeric antigen receptor-modified T cells
#732Universal anti-CD22 chimeric antigen receptor engineered immune cells
#733ANTIBODY-MODIFIED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELL AND USES THEREOF
#734ANTIBODY VARIANTS HAVING MODIFICATIONS IN THE CONSTANT REGION
#735Humanized DR4 antibody gene having apoptosis-inducing activity and dual-acting chimeric antigen receptor T cell or natural killer cell therapeutic agent using same
#736COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO PD-L1
#737METHODS FOR ADOPTIVE CELL THERAPY TARGETING ROR1
#738TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR
#739FC binding fragments comprising a PD-L1 antigen-binding site
#740Production of engineered T-cells by sleeping beauty transposon coupled with methotrexate selection
#741Immunomodulatory fusion proteins
#742MULTISPECIFIC BINDING PROTEINS TARGETING CEA
#743Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4
#744Bispecific antibody construct directed to MUC17 and CD3
#745HLA-G specific chimeric antigen receptor, nucleic acid, HLA-G specific chimeric antigen receptor expression plasmid, HLA-G specific chimeric antigen receptor expressing cell, use thereof, and pharmaceutical composition for treating cancer
#746Bispecific antibody and uses thereof
#747COMPOSITION OF BISPECIFIC ANTIBODIES AND METHOD OF USE THEREOF
#748Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof
#749Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
#750Hinge area and use of same in constructing car skeleton
#751NK-92 Bone and Brain targeting
#752General sequence of chimeric antigen receptor, chimeric antigen receptor and an application thereof
#753CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
#754Chimeric antibody/T-cell receptor constructs and uses thereof
#755Universal chimeric antigen receptor T cells specific for CD22
#756RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF NEUROMYELITIS OPTICA
#757Disrupting tumor tissues by targeting fibroblast activation protein (FAP)
#758REGULATABLE CHIMERIC ANTIGEN RECEPTOR
#759ANTI-cMET ANTIBODY
#760FC VARIANTS WITH REDUCED EFFECTOR FUNCTION
#761COMBINATION THERAPY OF CANCER INVOLVING MULTI-SPECIFIC BINDING PROTEINS THAT ACTIVATE NATURAL KILLER CELLS
#762PD-L1 -binding molecules comprising Shiga toxin A subunit scaffolds
#763FLT3L-FC fusion proteins
#764PSMA and CD3 Bispecific T Cell Engaging Antibody Constructs
#765Vaccine molecules
#766FUSION PROTEIN COMPRISING MULTIPLE HINGE SEQUENCES
#767IgG4 Fc fragment comprising modified hinge region
#768Chimeric Antigen Receptor T Regulatory Cells for the Treatment of Atherosclerosis
#769Enhanced immune cells using dual shRNA and composition including the same
#770Adhesion Receptor Constructs and Uses Thereof in Natural Killer Cell Immunotherapy
#771Compositions for inhibiting MASP-2 dependent complement activation
#772Materials and methods for improved single chain variable fragments
#773Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
#774FLT3L-based chimeric proteins
#775Antibodies to canine interleukin-4 receptor alpha
#776Chimeric antigen receptors against multiple HLA-G isoforms
#777Antigen binding molecule formats
#778CHIMERIC FC RECEPTOR BINDING PROTEINS AND USES THEREOF
#779Serpin fusion polypeptides and methods of use thereof
#780CHIMERIC ENGULFMENT RECEPTORS AND USES THEREOF FOR NEURODEGENERATIVE DISEASES
#781FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
#782Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
#783METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#784METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#785BISPECIFIC ANTIBODIES TO TNF-ALPHA AND IL-1BETA AND USES THEREOF
#786Recombinant immunoglobulin heavy chains comprising a sortase conjugation loop and conjugates thereof
#787Methods of treating neutorpenia using G-CSF protein complex
#788GENETIC ENGINEERING OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES
#789NOVEL HUMANIZED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR, ITS NUCELIC ACID SEQUENCE AND ITS PREPARATION
#790Transgene genetic tags and methods of use
#791Anti-interleukin-33 antibodies and uses thereof
#792Serpin fusion polypeptides and methods of use thereof
#793Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
#794Genetic engineering of non-human animals for the production of chimeric antibodies
#795GENETIC ENGINEERING OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES
#796Genetic engineering of non-human animals for the production of chimeric antibodies
#797Articles and methods directed to personalized therapy of cancer
#798Dimeric antigen receptors
#799Trispecific binding proteins, methods, and uses thereof
#800Site-specific antibody-drug conjugates
#801IL-21 (heterodimeric Fc-fused IL-21) fused to immunoglobulin heavy chain constant region heterodimer (heterodimeric Fc), and pharmaceutical composition comprising same
#802Method for generating multispecific antibodies from monospecific antibodies
#803HUMAN MONOCLONAL ANTI-PD-L1 ANTIBODIES AND METHODS OF USE
#804DUAL CAR EXPRESSING T CELLS INDIVIDUALLY LINKED TO CD28 AND 4-1BB
#805Genetic engineering of non-human animals for the production of chimeric antibodies
#806Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors
#807ARTICLES AND METHODS DIRECTED TO PERSONALIZED THERAPY OF CANCER
#808IgG Fc variants for veterinary use
#809Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors
#810NOVEL TNF FAMILY LIGAND TRIMER-CONTAINING ANTIGEN BINDING MOLECULES
#811Engineered phagocytic receptor compositions and methods of use thereof
#812Engineered phagocytic receptor compositions and methods of use thereof
#813IMMORTALIZED CAR-T CELLS GENETICALLY MODIFIED TO ELIMINATE T-CELL RECEPTOR AND BETA 2-MICROGLOBULIN EXPRESSION
#814Inert format
#815Assembly of bispecific antibodies
#816BISPECIFIC ANTIBODY
#817Enhanced chimeric antigen receptors and uses thereof
#818Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies
#819Chimeric engulfment receptor molecules and methods of use
#820HINGE MODIFIED ANTIBODY FRAGMENTS AND METHODS OF MAKING
#821Chimeric antigen receptors targeted to PSCA
#822Non-antagonistic antibodies directed against the alpha chain of the IL7 receptor extracellular domain and use thereof in cancer treatment
#823Chimeric Natural Killer Cell Receptors and Method of Using Thereof
#824Heterodimeric proteins for modulating gamma delta T cells
#825ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS
#826PHARMACEUTICAL COMPOSITION COMPRISING PEGYLATED FAB' FRAGMENT OF ANTI-HUMAN NGF ANTIBODY
#827Engineered opsonin for pathogen detection and treatment
#828Nanoparticle compositions and methods for immunotherapy
#829Cell secreted minibodies and uses thereof
#830Anti-BCMA chimeric antigen receptors
#831Engineered opsonin for pathogen detection and treatment
#832Anti-GD2 antibody
#833Bispecific polypeptide complexes
#834Bispecific CD3/CD19 polypeptide complexes
#835GLP-1 FUSION PROTEINS AND USES THEREOF
#836CHIMERIC ANTIGEN RECEPTOR COMPOSITIONS
#837TETRAVALENT ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
#838PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#839Immunoconjugates with an intracellularly-cleavable linkage
#840ARTICLES AND METHODS DIRECTED TO PERSONALIZED THERAPY OF CANCER
#841ANTIBODY HAVING ENHANCED ACTIVITY, AND METHOD FOR MODIFYING SAME
#842Means and methods for treating and diagnosing fibrosis or fibrosis-associated diseases
#843ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS
#844GAMMA DELTA T CELLS AND USES THEREOF
#845Heterodimeric antibody Fc-containing proteins and methods for production thereof
#846Multispecific binding proteins with mutant fab domains
#847CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents
#848Long-acting G-CSF for preventing neutropenia or reducing duration of neutropenia
#849Multispecific antibodies against CD40 and CD137
#850ANTIBODIES AGAINST PD-L1
#851Homodimeric protein constructs
#852PROTEINS BINDING GD2, NKG2D AND CD16
#853GPRC5D chimeric antigen receptors and cells expressing the same
#854Anti-c-Met antibody and use thereof
#855Proteins binding HER2, NKG2D and CD16
#856Dual chimeric antigen receptor-t cell which can be regulated, construction method therefor and use thereof
#857Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
#858Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods
#859Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereof
#860PROTEINS BINDING NKG2D, CD16, AND EGFR, HLA-E, CCR4, OR PD-L1
#861Anti-PD1 antibodies and their use as therapeutics and diagnostics
#862Heterodimeric proteins for modulating gamma delta T cells
#863Combination of a Treg depleting anti-4-1BB antibody and anti-PD1 antibody
#864T CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR
#865Trifunctional molecule and application thereof
#866Humanized or chimeric CD3 antibodies
#867Methods of use of soluble CD24 for treating immune related adverse events in cancer therapies
#868Cell engaging binding molecules
#869Genetic engineering of non-human animals for the production of chimeric antibodies
#870Genetic engineering of non-human animals for the production of chimeric antibodies
#871OCTS technology-based pancreatic cancer and malignant mesothelioma CAR-T therapeutic vector, construction method therefor, and use thereof
#872Malignant glioma CAR-T therapeutic vector based on OCTS technology, and construction method and application thereof
#873METHODS OF USE OF SOLUBLE CD24 FOR NEUROPROTECTION AND REMYELINATION
#874SPD-1 variant# FC fusion proteins
#875Car T-cells recognizing cancer-specific IL 13Ra2
#876Antibodies and chimeric antigen receptors specific for CD19
#877Bispecific binding proteins and uses thereof
#878Heterodimerizing Ig domains
#879Immunologic effector cell of targeted CLD18A2, and preparation method and use thereof
#880CD123 binding proteins and related compositions and methods
#881PROTEINS BINDING NKG2D, CD16 AND FLT3
#882REMOVAL OF TARGET CELLS BY CIRCULATING VIRUS-SPECIFIC CYTOTOXIC T-CELLS USING MHC CLASS I COMPRISING COMPLEXES
#883PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#884Antibodies of the class IGG4
#885PROTEINS BINDING NKG2D, CD16 AND ROR1 OR ROR2
#886NOVEL THERAPEUTIC ENZYME FUSION PROTEIN AND USE THEREOF
#887MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH
#888Anti-PVRIG antibodies and methods of use
#889PROTEASE BASED SWITCH CHIMERIC ANTIGEN RECEPTORS FOR SAFER CELL IMMUNOTHERAPY
#890Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection
#891ApoC-II mimetic peptides
#892PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
#893Light chain variable regions
#894Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders
#895scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificity
#896Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy
#897Bispecific heterodimeric fusion proteins containing IL-15-IL-15Ralpha Fc-fusion proteins and immune checkpoint antibody fragments
#898Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
#899Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
#900CSF1R-based chimeric proteins